🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Global Health Concern

Gonorrhoea infections are escalating around the world, with estimates suggesting more than 82 million new cases per year. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the face of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This medication, which is also used to treat urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization marks a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Global Access

As per results published in a major medical journal, the new drug cured over nine in ten of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The research involved nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the rights to make available and distribute the drug in numerous regions with limited resources.

Clinicians treating patients have shared optimism. The availability of a one-pill regimen like this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as essential to lessen the impact of the disease for people and to stop the proliferation of untreatable gonorrhoea worldwide.